ZUG, Switzerland, June  11, 2026  (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) (&#34;Oculis&#34; or the &#34;Company&#34;), a global biopharmaceutical company focused on breakthrough innovations to address significant

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

Oculis to present Privosegtor data; PIONEER milestones lift ON program

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) (&amp;#34;Oculis&amp;#34; or the &amp;#34;Company&amp;#34;), a global biopharmaceutical company focused on breakthrough innovations to address significant
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Oculis is set to present Privosegtor progress at Clinical Trials at the Summit 2026, highlighting its PIONEER registrational program for optic neuritis. The company has FDA Breakthrough Therapy and EMA PRIME designations, plus an FDA Special Protocol Assessment for PIONEER-1, underscoring a favorable regulatory path as Phase 2 ACUITY data showed neuroprotective signals.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Oculis to present Privosegtor data at Clinical Trials Summit 2026.</li><li>Privosegtor advances in the PIONEER registrational program with Breakthrough Therapy and PRIME designations.</li><li>Phase 2 ACUITY data suggest neuroprotection and retinal preservation signals.</li><li>PIONEER-1 has FDA SPA; potential ON/NAION registrations amid regulatory momentum.</li><li>ON incidence US &gt;30,000 annually; no approved neuroprotective therapy yet.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Oculis Holding AG (OCS): Announced Summit presentation for Privosegtor; progressing toward registrational trials with supportive regulatory milestones.</li><li>Privosegtor (N/A): Core investigational asset advancing in PIONEER; positive Phase 2 ACUITY data and potential CNS/optic indications.</li></ul>
 </section>

 <section data-block="category">
 <h3>Industry News</h3>
 Category: Industry News. The release reports pipeline progress, key regulatory milestones, and a forthcoming investor-facing presentation, all typical drivers of near-term biotech stock movement.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Upcoming Privosegtor data presentation at Summit 2026 could trigger near-term upside.</li><li>FDA Breakthrough Therapy and EMA PRIME designations support faster regulatory trajectory.</li><li>FDA SPA for PIONEER-1 lowers development risk for registrational trials.</li><li>NAION opportunity could expand Privosegtor&#039;s addressable market.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Date/time: June 13, 2026, 5:52 PM PDT, Privosegtor presentation by CEO Dr. Riad Sherif.</li><li>Privosegtor is a peptoid small molecule crossing blood-brain and retinal barriers.</li><li>ACUITY Phase 2 data showed neuroprotective potential and retinal preservation signals.</li><li>Breakthrough Therapy designation (FDA) and PRIME designation (EMA) for ON; Orphan Drug designations (FDA/EMA).</li><li>PIONEER program includes two ON registrational trials and one NAION trial; FDA SPA for PIONEER-1.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Bullish on OCS over the next 6–12 months as PIONEER milestones and Summit data could re-rate the stock.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OCS">OCS</a>, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada. Oculis is a proud sponsor of Clinical Trials at the Summit 2026, which brings together experts from around the world to discuss ongoing clinical trials and the latest data, all with the goal of achieving advances in vitreoretinal care. Details of Oculis' presentation are as follows: Clinical Trials at the Summit 2026: <ul type="disc"><li>Privosegtor in Optic Neuritis: From Discovery to PIONEER Registrational Trials Presenter: Riad Sherif, M.D., Chief Executive Officer Date/Time: Saturday, June 13, 2026; 5:52 PM PDT </li></ul> The presentation will highlight the development journey of Privosegtor, a peptoid small molecule that can cross both the blood-brain and retinal barriers and has the potential to become the first neuroprotective therapy for optic neuritis (ON), with potential broad applicability in other neuro-ophthalmic and neurological diseases. Following the successful Phase 2 ACUITY trial and the granting of Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for ON and PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA), Oculis is advancing the PIONEER registrational program for Privosegtor in optic neuropathies, with the PIONEER-1 trial in optic neuritis. "Privosegtor is advancing through our PIONEER registrational program, offering the potential to address significant unmet medical needs in optic neuritis and other optic neuropathies where there are currently no approved neuroprotective therapies to prevent visual impairment," said Riad Sherif, M.D., Chief Executive Officer of Oculis. "Our progress is supported by encouraging Phase 2 ACUITY data and key regulatory milestones, including Breakthrough Therapy and PRIME designations, and an FDA Special Protocol Assessment for PIONEER-1, which we believe support our strategic direction. We look forward to discussing the PIONEER program at Clinical Trials at the Summit as we navigate late-stage development with the aim of delivering potential transformative new options for patients." About Privosegtor Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor's neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina (GCIPL and RNFL layers) and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis, and multiple sclerosis (MS), where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility (clinical function disability) in the MS model. Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) as well as Orphan Drug designation from both the FDA and the EMA for ON. Privosegtor is currently being evaluated in Oculis' PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy (NAION). In addition to its potential neuroprotective effect on the optic nerve, Privosegtor could also have wide applicability in treating other neuro-ophthalmic and neurological indications. Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. About Optic Neuritis Optic Neuritis (ON) is a rare condition characterized by an acute inflammation of the optic nerve that can lead to permanent visual impairment. It affects up to 8 in 100,000 people worldwide with a U.S. annual incidence estimated to be &gt;30,000 and often represents the first sign of multiple sclerosis1,2. It mainly occurs in adults between the age of 20 and 40 years and is more frequent in women (2:1)3. ON is a type of neuropathy (nerve disease) that happens when acute inflammation of the optic nerve affects the signals traveling from the eyes through the brain, causing pain, vision loss and other symptoms. The cells that make up the optic nerve have a lipid protective coating called a myelin sheath, which is preferentially damaged in ON. Without myelin, the optic nerve cells can't send signals properly and axons can be irreversibly lost. To date there is no specific therapy approved for acute optic neuritis and the unmet needs remain for therapies that can prevent vision loss after an acute episode by reducing nerve cell permanent damage or death. About Oculis Oculis is a global biopharmaceutical company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OCS">OCS</a>, XICE: OCS)) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis' highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neurological diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: <a href="https://www.globenewswire.com/Tracker?data=g6Ubqnysp8Wzu9Sfh968hfrvTVc0K2vJVMzLdgr0hSR8IPqcayjlLQujkhz2EXg1lXim0abdxkVbnootzj7kddaGrEaS_wrGXg7E-5Q_INs=" rel="nofollow" target="_blank">www.oculis.com</a> Oculis Contacts Ms. Sylvia Cheung, CFO <a href="https://www.globenewswire.com/Tracker?data=QGMOIPv5DSsH5HSe3z30-umY85jj6GR0OT6dZ0VQxJoMYMJw7oM11WFRooOL1T2_TCogHQYL-hqRVgHJuKUogJdOH51uvu64MrD4F4U0qjEABzCZ-_gGwKwnenYKoAZs" rel="nofollow" target="_blank">sylvia.cheung@oculis.com</a> Investor Relations LifeSci Advisors Corey Davis, Ph.D. <a href="https://www.globenewswire.com/Tracker?data=KabKeL4aGcaJ1jwLNrw6WCpv1hS3oV5gUxE_3dtjUrodg87J9v4H3fToFEpKDSGldLcw3qLHmpRMe2pqnRrVEEjBK_2KMSZl8NAKtQ8kBgpoNPEus2WzRXJ5S4U2KPP0" rel="nofollow" target="_blank">cdavis@lifesciadvisors.com</a> Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous <a href="https://www.globenewswire.com/Tracker?data=HhdEUQ-JYhQjsU2urcmXP4e9xzd69TG2XOGmoIoJ27J23IHuL55hdXkmIUOXVZUicrInvtAga8CZ8nRlkQdaDgrlY8osccrONHBWOkJs3B4ifBgRiUET2rMHBGOH-YPh" rel="nofollow" target="_blank">oculis@icrhealthcare.com</a> Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company's product candidates, including the initiation, timing, progress and results of current and future clinical trials, the potential of Privosegtor to become the first neuroprotective therapy for ON and provide transformative treatment options to patients, as well as its broader potential in other indications, Oculis' research and development programs, regulatory and business strategy; expected milestones; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis' control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis' annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC's website, <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE4NzA3NCM0MDI0MDcwNjAjMjE4OTAyMw=="></img> <img alt="" src="https://ml-eu.globenewswire.com/media/ZjhkNGE4YTgtNTg3ZC00NGJhLTk5ZWItODk2MTMwNGY0MDNlLTEyMDA1NzYtMjAyNi0wNi0xMS1lbg==/tiny/Oculis-Holding-AG.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/f6fa6e90-83a4-4baa-a3b6-5483017d26b9"><img src="https://ml-eu.globenewswire.com/media/f6fa6e90-83a4-4baa-a3b6-5483017d26b9/small/oculis-logo-gradient-jpg-resized-jpg.jpg" border="0" width="150" height="37" alt="Primary Logo"></img></a>

Oculis is set to present Privosegtor progress at Clinical Trials at the Summit 2026, highlighting its PIONEER registrational program for optic neuritis. The company has FDA Breakthrough Therapy and EMA PRIME designations, plus an FDA Special Protocol Assessment for PIONEER-1, underscoring a favorable regulatory path as Phase 2 ACUITY data showed neuroprotective signals.

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News